0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Special Feature |

Pathological Case of the Month FREE

Arch Pediatr Adolesc Med. 1999;153(12):1307-1308. doi:.
Text Size: A A A
Published online

DIAGNOSIS AND DISCUSSION: DIABETIC NEPHROPATHY IN CYSTIC FIBROSIS

Figure 1. Microscopic section of the renal biopsy specimen showing mesangial hypercellularity and matrix increase. Glomerular arterioles exhibit hyaline change (hematoxylin-eosin, original magnification ×200.)

Figure 2. Microscopic section showing increased mesangial matrix (Masson trichrome, original magnification ×200).

Figure 3. Microscopic section showing mild atherosclerosis (hematoxylin-eosin, original magnification ×220).

Figure 4. Electron photomicrograph demonstrating mildly thickened glomerular basement membranes and increased mesangial matrix (uranyl acetate–lead citrate, original magnification ×15,000).

Figure 5. Electron photomicrograph showing rare dense deposits in glomerular capillary loops (uranyl acetate–lead citrate, original magnification ×35,000).

The clinical history of DM implied that the glomerular, tubulointerstitial, and vascular scarring in this young patient was owing in part to early progression of diabetic nephropathy. A superimposed, mediated immune complex glomerulonephritis characterized by mesangial proliferation and rare immune deposits was present in the glomerular basement membranes (GBMs) and mesangia. The mesangial hypercellularity and distribution of sparse immune deposits, some of which were rarefied, suggested resolving postinfectious glomerulonephritis. This interpretation derives support from Abramowsky and Swinehart,1 who attributed similar mesangiopathic lesions to a postinfectious process in their study of nephropathy in young patients with CF.

Diabetes mellitus nephropathy is characterized pathologically by histologic changes that occur in the GBMs, mesangial matrix, and vasculature. The GBM is thickened by a homogeneous hyaline structure that is periodic acid–Schiff positive. Mild proliferation of mesangial cells with notable matrix increase when combined with thickened GBM leads to diffuse glomerulosclerosis. The pathogenesis of the disease is hypothesized to be due to 4 factors: (1) metabolic defect of increased glucose or decreased insulin with direct effects; (2) increased type IV collagen and fibronectin in the GBM with decreased proteoglycan; (3) new enzymatic glycosylation of proteins, ie, the GBM collagen; and (4) increased glomerular filtration rate and glomerular hypertrophy.2

The increased life expectancy of patients with CF observed over the last 25 years has been associated with an increased prevalence of DM in the population with CF.3 Patients with CF with long-standing DM are at increased risk for developing microangiopathic effects on the eyes, kidneys, and nervous system much like patients with DM without CF.

Reports from 6 studies49 of patients with CF found that 4.9% to 14.7% of patients with CF were clinically diagnosed as having DM. The CF genotype also seems to play a major role in the development of DM in patients with CF. Rosenecker et al4 found that 75% and 19% of 39 patients with CF and DM, respectively, had homozygous and heterozygous ΔF508 gene deletions. Age of onset tends to be in the second decade of life, but has been reported as early as age 2 years.10 The cause of diabetes in patients with CF has been attributed to decreased beta-islet cell number and reduced insulin levels and C-peptide activity.11 Insulin resistance has been noted to influence glucose tolerance in CF.12 Pancreatic fibrosis along with these other pancreatic changes are believed to play a major role in the incidence of DM in patients with CF.

Diabetic microangiopathy, as in our patient, is becoming more important as longevity increases for patients with CF. Sullivan and Denning11 studied 19 patients with CF and DM from 1978 through 1987 and found that 4 (21%) had microangiopathic complications secondary to DM. This development of multisystem microvascular disease in 3 patients after having DM for 10 years is similar to the pattern seen in patients with DM without CF.11 Our patient's presentation was atypical and accelerated compared with the usual documented progression of complications from DM. As with this patient, the clinician needs to be increasingly alert for presentations of microangiopathic changes of DM in patients with CF who have DM.

Accepted for publication April 30, 1999.

Reprints: Mark Weatherly, MD, Nemours Children's Foundation, 83 W Columbia St, Orlando, FL 32806.

Abramowsky  RSwinehart  GL The nephropathy of cystic fibrosis: a model of chronic nephrotoxicity. Hum Pathol. 1982;13934- 939
Link to Article
Cotran  RSKumar  VRobbins  SL Robbin's Pathologic Basis of Disease.  Philadelphia, Pa WB Saunders Co1994;961- 963
Rodman  HMDoershuk  CFRoland  JM The interaction of two diseases: diabetes mellitus and cystic fibrosis. Medicine (Baltimore). 1986;65389- 397
Link to Article
Rosenecker  JEichler  IKuhn  L  et al.  Genetic determination of diabetes mellitus in patients with cystic fibrosis. J Pediatr. 1995;127441- 443
Link to Article
Reisman  JCorey  MCanny  G  et al.  Diabetes mellitus in patients with cystic fibrosis: effect on survival. Pediatrics. 1990;86374- 377
Finkelstein  SMWielinski  CLElliot  GR  et al.  Diabetes mellitus associated with cystic fibrosis. J Pediatr. 1988;112373- 377
Link to Article
Kreuger  LJLerner  AKatz  SM  et al.  Cystic fibrosis and diabetes mellitus: interactive or idiopathic? J Pediatr Gastroenterol Nutr. 1991;13209- 219
Link to Article
Hayes  FJO'Brien  AO'Brien  C  et al.  Diabetes mellitus in an adult cystic fibrosis population. Ir Med J. 1994;8759- 60
Lanng  SThorsteinsson  BLund-Anderson  C  et al.  Diabetes mellitus in Danish cystic fibrosis patients: prevalence and late diabetic complications. Acta Paediatr. 1994;8372- 77
Link to Article
Pfeifer  T Diabetes in cystic fibrosis. Clin Pediatr. November1992;682- 687
Sullivan  MMDenning  CR Diabetic microangiopathy in patients with cystic fibrosis. Pediatrics. 1989;84642- 647
Culler  FLMcKean  LPBuchanan  CN  et al.  Glipizide treatment of patients with cystic fibrosis and impaired glucose tolerance. J Pediatr Gastroenterol Nutr. 1994;18375- 378
Link to Article

Tables

References

Abramowsky  RSwinehart  GL The nephropathy of cystic fibrosis: a model of chronic nephrotoxicity. Hum Pathol. 1982;13934- 939
Link to Article
Cotran  RSKumar  VRobbins  SL Robbin's Pathologic Basis of Disease.  Philadelphia, Pa WB Saunders Co1994;961- 963
Rodman  HMDoershuk  CFRoland  JM The interaction of two diseases: diabetes mellitus and cystic fibrosis. Medicine (Baltimore). 1986;65389- 397
Link to Article
Rosenecker  JEichler  IKuhn  L  et al.  Genetic determination of diabetes mellitus in patients with cystic fibrosis. J Pediatr. 1995;127441- 443
Link to Article
Reisman  JCorey  MCanny  G  et al.  Diabetes mellitus in patients with cystic fibrosis: effect on survival. Pediatrics. 1990;86374- 377
Finkelstein  SMWielinski  CLElliot  GR  et al.  Diabetes mellitus associated with cystic fibrosis. J Pediatr. 1988;112373- 377
Link to Article
Kreuger  LJLerner  AKatz  SM  et al.  Cystic fibrosis and diabetes mellitus: interactive or idiopathic? J Pediatr Gastroenterol Nutr. 1991;13209- 219
Link to Article
Hayes  FJO'Brien  AO'Brien  C  et al.  Diabetes mellitus in an adult cystic fibrosis population. Ir Med J. 1994;8759- 60
Lanng  SThorsteinsson  BLund-Anderson  C  et al.  Diabetes mellitus in Danish cystic fibrosis patients: prevalence and late diabetic complications. Acta Paediatr. 1994;8372- 77
Link to Article
Pfeifer  T Diabetes in cystic fibrosis. Clin Pediatr. November1992;682- 687
Sullivan  MMDenning  CR Diabetic microangiopathy in patients with cystic fibrosis. Pediatrics. 1989;84642- 647
Culler  FLMcKean  LPBuchanan  CN  et al.  Glipizide treatment of patients with cystic fibrosis and impaired glucose tolerance. J Pediatr Gastroenterol Nutr. 1994;18375- 378
Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
JAMAevidence.com